Tempus AI rises after study shows AI-driven alerts improve heart valve treatment

Medtronic

01/04/2026 15:53

** Shares of genetics-testing firm Tempus AI TEM.O rise 3.56% to $46.83

** Co says a collaboration study with medical device maker Medtronic MDT.N showed AI-driven alerts sent through electronic health records improved timely evaluation and treatment of patients with aortic stenosis or mitral regurgitation, two serious heart valve diseases

** Study showed patients in the alert group were 27% more likely to be evaluated by a specialist heart team or receive a valve procedure than those getting usual care, meeting its main goal - TEM

** Within 90 days of the heart scan, the alerts raised valve procedures to 13.4% from 9.6% and specialist heart team evaluations to 22.7% from 17.9% - TEM

** TEM shares rose over 74% in 2025

 (Reporting by Kunal Das in Bengaluru)

 ((Kunal.Das2@thomsonreuters.com;))